122 related articles for article (PubMed ID: 32386490)
1. PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Gevaert T; Cimadamore A; Montironi R; Eckstein M
Curr Drug Targets; 2021; 22(2):162-170. PubMed ID: 32386490
[TBL] [Abstract][Full Text] [Related]
2. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
3. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
[TBL] [Abstract][Full Text] [Related]
4. Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.
Ionescu DN; Downes MR; Christofides A; Tsao MS
Curr Oncol; 2018 Jun; 25(3):e209-e216. PubMed ID: 29962847
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Lung Cancer.
Yu H; Boyle TA; Zhou C; Rimm DL; Hirsch FR
J Thorac Oncol; 2016 Jul; 11(7):964-75. PubMed ID: 27117833
[TBL] [Abstract][Full Text] [Related]
6. Alix-normalized exosomal programmed death-ligand 1 analysis in urine enables precision monitoring of urothelial cancer.
Woo HK; Park J; Kim KH; Ku JY; Ha HK; Cho YK
Cancer Sci; 2024 May; 115(5):1602-1610. PubMed ID: 38480462
[TBL] [Abstract][Full Text] [Related]
7. Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions.
Miller EJ; Galsky MD
Curr Treat Options Oncol; 2023 Dec; 24(12):1870-1888. PubMed ID: 38085403
[TBL] [Abstract][Full Text] [Related]
8. Reinforcement Learning and PK-PD Models Integration to Personalize the Adaptive Dosing Protocol of Erdafitinib in Patients with Metastatic Urothelial Carcinoma.
De Carlo A; Tosca EM; Fantozzi M; Magni P
Clin Pharmacol Ther; 2024 Apr; 115(4):825-838. PubMed ID: 38339803
[TBL] [Abstract][Full Text] [Related]
9. The journey of determining PD-L1 expression in muscle-invasive urothelial carcinoma.
Algaba F
Actas Urol Esp (Engl Ed); 2024 May; ():. PubMed ID: 38754731
[No Abstract] [Full Text] [Related]
10. Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice.
Raleigh DR; Chen WC; Gondi V; Rogers L; Mehta M
J Neurooncol; 2024 May; ():. PubMed ID: 38743346
[No Abstract] [Full Text] [Related]
11. PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Rouanne M; Radulescu C; Adam J; Allory Y
World J Urol; 2021 May; 39(5):1345-1355. PubMed ID: 33141317
[TBL] [Abstract][Full Text] [Related]
12. Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.
Bösherz MS; Samarska IV; Gaisa NT
Methods Mol Biol; 2023; 2684():3-25. PubMed ID: 37410225
[TBL] [Abstract][Full Text] [Related]
13. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
Alameddine R; Mallea P; Shahab F; Zakharia Y
Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
[TBL] [Abstract][Full Text] [Related]
14. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Rouprêt M; Seisen T; Birtle AJ; Capoun O; Compérat EM; Dominguez-Escrig JL; Gürses Andersson I; Liedberg F; Mariappan P; Hugh Mostafid A; Pradere B; van Rhijn BWG; Shariat SF; Rai BP; Soria F; Soukup V; Wood RG; Xylinas EN; Masson-Lecomte A; Gontero P
Eur Urol; 2023 Jul; 84(1):49-64. PubMed ID: 36967359
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Balar AV; Castellano DE; Grivas P; Vaughn DJ; Powles T; Vuky J; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Necchi A; Petrylak DP; Plimack ER; Xu JZ; Imai K; Moreno BH; Bellmunt J; de Wit R; O'Donnell PH
Ann Oncol; 2023 Mar; 34(3):289-299. PubMed ID: 36494006
[TBL] [Abstract][Full Text] [Related]
16. The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma.
Cathomas R; Lorch A; Bruins HM; Compérat EM; Cowan NC; Efstathiou JA; Fietkau R; Gakis G; Hernández V; Espinós EL; Neuzillet Y; Ribal MJ; Rouanne M; Thalmann GN; van der Heijden AG; Veskimäe E; Alfred Witjes J; Milowsky MI;
Eur Urol; 2022 Jan; 81(1):95-103. PubMed ID: 34742583
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
18. Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies.
Evmorfopoulos K; Mitrakas L; Karathanasis A; Zachos I; Tzortzis V; Vlachostergios PJ
Biomedicines; 2023 Jun; 11(7):. PubMed ID: 37509415
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression.
Salhi Y; De Wit R; Robbrecht D
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509315
[TBL] [Abstract][Full Text] [Related]
20. Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
Nishiyama H; Tsuzuki T; Ohyama C; Matsuyama H; Shinozaki K; Hayashi Y; Hayashi N; Koto R; Shin E; Ogawa O
Int J Clin Oncol; 2023 Oct; 28(10):1398-1410. PubMed ID: 37498492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
